ProgrammableMarketing/exonic.ai (opens in a new tab)
PDF

Views

  • Plan
  • Roadmap
  • Research

On this page

  • The brief
  • Start here
  • Idea portfolio
  • Effort vs impact
  • This week · 7
  • This quarter · 10
  • Big bets · 3
  • Wildcards · 2
  • How we can help
Generated Nov 10, 2026
  1. Programmable
  2. Playbooks
  3. Exonic
Exonic logo

growth playbook · Nov 10, 2026

exonic.ai (opens in a new tab)

Exonic growth playbook

Diagnosis

Exonic is a three-person YC Fall 2025 biotech that designs synthetic regulatory DNA with AI and is hiring a founding wet-lab scientist for cell-type targeting and AAV manufacturing. The science story is promising, but the public record is thin and scattered.

Its own site shows one line of text to every search engine, AI assistant and link preview, has no sitemap and weighs 13.8 MB. Directories still describe an older "crowdsourcing drug discovery" company and disagree on funding and founders. A Vertex-owned AAV company is called Exonics, one letter away.

This playbook fixes the site and the record first, then turns the HepG2 enhancer result into a preprint, an open benchmark and two paid pilot offers (manufacturing yield and cell-type targeting), before the bigger choices: licensing terms, an in-house program and non-dilutive funding.

Growth Score

5/10

Biggest Opportunity

Turn lab-validated enhancer designs into proof partners can check (a preprint, a benchmark and a crawlable site), and sell a short, fixed-scope pilot to AAV manufacturers and gene therapy teams before the company has to fund a whole therapy.

Biggest Risk

With a team of three, an unverified headline claim and better-funded rivals (Dyno, Asimov, Profluent) already selling AI-designed genetic parts, partners may simply not find or trust Exonic before the next raise.

01

Start here

The three moves to make first. Each one is written up in full below.

  1. 1

    Serve real pages: today exonic.ai shows search engines, AI assistants and link previews one line of text

    Fetch exonic.ai/team with JavaScript off, confirm only the title line comes back, and list the five pages to prerender.

    High impact First result in 1-2 weeks
  2. 2

    Publish a one-page fact sheet on /media to settle what directories get wrong

    List every directory profile found and note what each gets wrong.

    High impact First result in 2-4 weeks
  3. 3

    Say one thing everywhere: "AI for adaptive medicine" on the site, "cell and gene therapeutics" on YC, "crowdsourcing" in directories

    Write three candidate sentences and test them on two advisors.

    High impact First result in 1 month

02

Your idea portfolio

22 ideas, grouped by when to run them. Open any idea for how to run it: the steps, who to approach, copy you can use, and how to measure it.

  • 7 ideas are marked Unexpected: plays you are unlikely to have tried.

Every idea placed by the effort it takes against the impact it could have. Quick wins sit top left; select a number to open that idea. The filters below narrow the list by status, timing, category and what Programmable can build.

Effort vs impactEach number is an idea. Select one to open it.
Impact →
Quick wins · 5Big bets · 7Fill-ins · 7Reconsider · 3
Effort →

Showing 22 of 22 ideas

This week 7

Quick wins with a clear first action.

  • 01

    We fetched exonic.ai seven ways on November 10, 2026: the homepage with and without www, /team, /media/cre, /studio, /sitemap.xml and a made-up address. Every one returned the same thing to a reader that does not run JavaScript: the line "Exonic – AI for adaptive medicine." The headline visitors see after scripts run ("Imagine if medicine could adapt to disease"), the team, the media page and the science never reach anything that reads raw HTML. That includes many AI crawlers, link previews in Slack, LinkedIn and email, and the scraping tools behind investor and partner databases. /sitemap.xml returns the same page instead of XML, so the site scan found 0 URLs. Made-up addresses also get the homepage instead of a "not found" page. Meanwhile directories fill the gap with an older "crowdsourcing drug discovery" story and conflicting facts. For a company whose buyers check the science before they reply to an email, the site is invisible exactly where it is being checked.

    High impactLow effort First result in 1-2 weeks Founder and CEO

    First action

    Fetch exonic.ai/team with JavaScript off, confirm only the title line comes back, and list the five pages to prerender.

    How to measure it

    Indexed pages showing real content

    Now
    –
    Target
    5 of 5 core pages, plus a correct preview on LinkedIn and X
    By
    30 days

    Steps

    1. 1

      Confirm the gap

      Fetch each page with JavaScript off and record what comes back; save it as the baseline.

      Founder and CEO 1 hour

    2. 2

      Write the page text

      One headline, one paragraph and a meta description each for home, team, media, studio and contact.

      Founder and CEO 1 day

    3. 3

      Prerender

      Switch those routes to static generation or server rendering so the text is in the first HTML response.

      Contract web developer 2-3 days

    4. 4

      Real sitemap and 404s

      Serve an XML sitemap of the real pages and a 404 status for unknown paths.

      Contract web developer half a day

    5. 5

      Add markup and previews

      Organization schema with links to YC, LinkedIn and X; Open Graph title, description and image on every page.

      Contract web developer half a day

    6. 6

      Submit and verify

      Submit the sitemap in Search Console and request indexing of the five pages.

      Founder and CEO 1 hour

    7. 7

      Check like a partner would

      Share links in LinkedIn and Slack, and ask two AI assistants "what does Exonic do?" a fortnight later.

      Founder and CEO 2 weeks

    First result
    1-2 weeks for previews; 2-4 weeks for search
    Cost
    2-4 days of developer time; no new tools
    Owner
    Founder and CEO

    Smallest test

    Prerender just the homepage with a real paragraph and meta description, then share it on LinkedIn and compare the preview.

    Why it works

    Prerender or statically export the pages that matter: home, team, media, studio and a new contact page. Each should have its real headline, a one-paragraph description of what Exonic does, a meta description, Open Graph tags and a canonical URL in the HTML the server sends. Generate a real sitemap.xml listing those pages and return a 404 status for addresses that don't exist. Add Organization markup that links to the YC profile, LinkedIn and X accounts. Then check the result the way a crawler would: fetch each page with JavaScript off, paste the URL into a LinkedIn post preview, and ask two AI assistants what Exonic does.

    Partners, investors and candidates now research a company through search, AI answers and link previews before any call, and all of those read the HTML first. Prerendering five pages is a few days of work on a Vercel-hosted site. It turns the site from one line into the main, citable source on Exonic, and it fixes how the site looks when shared at no extra cost.

    Ready to use

    ChecklistCrawlable-site checklist

    [ ] Home, team, media, studio and contact return their headline and a paragraph with JavaScript off
    [ ] Unique <title> and meta description per page
    [ ] Open Graph title, description and image per page
    [ ] Canonical URL on every page (www or apex, one only)
    [ ] /sitemap.xml returns XML listing the real pages
    [ ] Unknown paths return HTTP 404
    [ ] Organization schema with sameAs links to the YC profile, LinkedIn and X
    [ ] Sitemap submitted in Search Console
    [ ] LinkedIn and Slack previews checked

    Risks and how to handle them

    • Prerendering breaks interactive parts of the site

      Prerender only the text pages and leave Studio as a client-side app behind its own route.

    • The message is still in flux

      Write the page text after agreeing one description (idea 4); it can be edited later in minutes.

    Evidence

    • Your websiteEvery address fetched on November 10, 2026 (the homepage with and without www, /team, /media/cre, /studio, /sitemap.xml and a made-up path) returned the same thing to a reader that does not run JavaScript: the single line "Exonic – AI for adaptive medicine." robots.txt allows all crawlers.Source
    • Your websiteSite scan (November 10, 2026): three sitemap files read but 0 page URLs listed; 0 blog posts; no contact, about, careers or pricing page found; the homepage links to /team, a media page at /media/cre and one science@ email address.Source
    • PageSpeedMobile performance 25/100 (desktop 64). In Google's phone lab test the main content (the headline "Imagine if medicine could adapt to disease") appears after 14.4 s, with 27.6 s of blocking time; the homepage downloads 13.8 MB, including 2.7 MB of JavaScript and 5 KB of images. Largest fixes: cache lifetimes (about 11.8 s, 2.6 MB) and unused JavaScript (about 8.7 s, 2.0 MB). Real Chrome visitors (75th percentile) see the main content in 2.3 s, which passes, but responsiveness (INP) is 389 ms, above the 200 ms "good" line; layout shift is 0. Seven third-party services load, including Google Tag Manager (186 KB) and Google ad tags.Source
    • Directory profilesHealthcare Discovery's profile says nearly all public information about Exonic comes from directory listings and company statements. It found no paper or preprint for the HepG2 result and no NIH or NSF awards; funding appears as $500K (PitchBook, Tracxn, with different close dates) and as $1M elsewhere; some directories name founders that no other source confirms.Source
  • 02

    The homepage has almost no images (5 KB) yet downloads 13.8 MB, including 2.7 MB of JavaScript, and scores 25/100 on mobile. In the lab the headline takes 14.4 s to appear on a phone. Real Chrome visitors load it in 2.3 s, which passes, so loading is not the main problem for them. The problem they do feel is responsiveness: 389 ms for a tap to respond, almost twice the 200 ms "good" line.

    Medium impactLow effort First result in 1 day Contract web developer

    First action

    Add immutable cache headers for hashed assets in the Vercel config.

    How to measure it

    Field INP

    Now
    –
    Target
    under 200 ms
    By
    60 days

    Steps

    1. 1

      Cache assets

      Long cache lifetimes for hashed JS, CSS and fonts.

      Contract web developer 2 hours

    2. 2

      Split the bundle

      Load Studio and heavy libraries only on their own routes.

      Contract web developer 2 days

    3. 3

      Defer effects

      Load animation or 3D code after the headline renders.

      Contract web developer 1 day

    4. 4

      Trim fonts

      Self-host one or two font weights instead of 13 font requests.

      Contract web developer 2 hours

    5. 5

      Fix contrast

      The one accessibility issue: low colour contrast.

      Contract web developer 1 hour

    6. 6

      Re-test

      PageSpeed lab score now; field responsiveness after 28 days.

      Founder and CEO 1 month

    First result
    1 day for lab scores; 28 days for field data
    Cost
    2-4 developer days
    Owner
    Contract web developer

    Smallest test

    Add cache headers today and re-run PageSpeed.

    Why it works

    Set long cache lifetimes on static assets (the biggest single saving, about 2.6 MB). Split the JavaScript so the landing page doesn't ship Studio's code (about 2.0 MB unused). Lazy-load any 3D or animation code after first paint and trim the Google Fonts requests. Re-run PageSpeed and watch the real-visitor responsiveness figure over the next 28 days.

    Investors and scientists often open the link on a phone between meetings. A page that freezes on tap reads as unfinished, and lighter pages are also easier for crawlers to render.

    Risks and how to handle them

    • Visual design loses its effect

      Keep the effect, just load it after the text.

    Builds on

    Evidence

    • PageSpeedMobile performance 25/100 (desktop 64). In Google's phone lab test the main content (the headline "Imagine if medicine could adapt to disease") appears after 14.4 s, with 27.6 s of blocking time; the homepage downloads 13.8 MB, including 2.7 MB of JavaScript and 5 KB of images. Largest fixes: cache lifetimes (about 11.8 s, 2.6 MB) and unused JavaScript (about 8.7 s, 2.0 MB). Real Chrome visitors (75th percentile) see the main content in 2.3 s, which passes, but responsiveness (INP) is 389 ms, above the 200 ms "good" line; layout shift is 0. Seven third-party services load, including Google Tag Manager (186 KB) and Google ad tags.Source
  • 03

    One directory notes that almost everything public about Exonic comes from directory listings. Those listings disagree on funding ($500K or $1M, with different close dates) and name founders no other source confirms. Exonic already has a /media page, but it shows no content to crawlers.

    High impactLow effort First result in 2-4 weeks Founder and CEO

    First action

    List every directory profile found and note what each gets wrong.

    How to measure it

    Corrected profiles

    Now
    –
    Target
    5 major directories consistent
    By
    60 days

    Steps

    1. 1

      Audit profiles

      YC, Crunchbase, PitchBook, Tracxn and the AI startup directories.

      Founder and CEO half a day

    2. 2

      Write the facts

      Ten lines, each one checkable.

      Founder and CEO 2 hours

    3. 3

      Publish on /media

      Prerendered, with a date and a press contact.

      Contract web developer half a day

    4. 4

      Add a press kit

      Logo, a short and a long description, team photo.

      Founder and CEO half a day

    5. 5

      Request corrections

      Use each directory's claim or edit process.

      Founder and CEO 1 day

    6. 6

      Review quarterly

      Update after each raise or result.

      Founder and CEO quarterly

    First result
    2-4 weeks
    Cost
    $0
    Owner
    Founder and CEO

    Smallest test

    Claim and correct the Crunchbase profile this week.

    Why it works

    Turn /media into a crawlable fact sheet: a one-line description, founding year, YC batch, location, team size and roles, investors you are happy to name, the stage of the science (what is validated in cells and what is not), contact for partners and press, and logos. Then send correction requests to the main directories, linking to the page.

    Partners and investors cross-check directories. One canonical source the company controls stops each database inventing its own version, and AI assistants tend to quote the most authoritative page.

    Ready to use

    CopyFact sheet outline

    Exonic, in one line:
    Founded: 2025 · Y Combinator Fall 2025 · San Francisco
    Team: size and roles
    Investors: (names you choose to disclose)
    What we do: designed regulatory DNA for gene and cell therapies
    What is validated: (assays, cell lines, dates)
    What is next: (programs, without confidential detail)
    Partner and press contact:
    Last updated:

    Risks and how to handle them

    • Disclosing more than intended

      Publish only what you are happy for partners to quote; leave out what is confidential.

    Builds on

    Evidence

    • Directory profilesHealthcare Discovery's profile says nearly all public information about Exonic comes from directory listings and company statements. It found no paper or preprint for the HepG2 result and no NIH or NSF awards; funding appears as $500K (PitchBook, Tracxn, with different close dates) and as $1M elsewhere; some directories name founders that no other source confirms.Source
    • Your websiteSite scan (November 10, 2026): three sitemap files read but 0 page URLs listed; 0 blog posts; no contact, about, careers or pricing page found; the homepage links to /team, a media page at /media/cre and one science@ email address.Source
  • 04

    The site title changed from "Crowdsourcing Drug Discovery" to "AI for adaptive medicine". The YC profile says "an AI-native cell and gene therapeutics company" that programs DNA to be "context-aware". Directories still describe a crowdsourced drug-discovery competition and a no-code Studio. Three descriptions of one company make a partner unsure what they would be buying.

    High impactLow effort First result in 1 month Founder and CEO

    First action

    Write three candidate sentences and test them on two advisors.

    How to measure it

    Consistent descriptions

    Now
    –
    Target
    all owned profiles
    By
    30 days

    Steps

    1. 1

      Draft

      Three versions of one sentence and one paragraph.

      Founder and CEO 2 hours

    2. 2

      Test

      Ask two advisors and one prospective partner which is clearest.

      Founder and CEO 2 days

    3. 3

      Update the site

      Homepage text and meta description.

      Contract web developer 1 hour

    4. 4

      Update profiles

      YC, LinkedIn, X and Crunchbase.

      Founder and CEO 1 hour

    5. 5

      Update the deck

      First slide and email signature.

      Founder and CEO 1 hour

    6. 6

      Check AI answers

      Ask assistants what Exonic does a month later.

      Founder and CEO 1 month

    First result
    1 month
    Cost
    $0
    Owner
    Founder and CEO

    Smallest test

    Update the YC and LinkedIn descriptions today.

    Why it works

    Agree one sentence and one paragraph, for example: what Exonic designs (context-aware regulatory DNA), for whom (gene therapy developers and vector manufacturers) and the proof (designs validated in cells). Use it word for word on the site, YC, LinkedIn, X, the fact sheet and the pitch deck. Keep "adaptive medicine" as the vision line and the concrete sentence as the description.

    Search snippets, AI answers and directories copy whatever text appears most consistently. A concrete description also qualifies inbound interest.

    Risks and how to handle them

    • Narrowing too early

      Keep the vision line; only the description gets concrete.

    Evidence

    • Your websiteChange tracking since December 3, 2025: the site title changed from "Exonic – Crowdsourcing Drug Discovery" to "Exonic – AI for adaptive medicine." and Google Analytics was flagged as removed. The domain was registered in May 2025.Source
    • Y Combinator profile"Exonic is an AI-native cell and gene therapeutics company." "We program DNA sequences to be context-aware, unlocking new kinds of genetic therapies." Fall 2025 batch, founded 2025, team of 3, San Francisco; links to LinkedIn (exonicbio) and X (exonicai) accounts.Source
    • Directory profilesStartupHub describes Exonic as aiming to make drug discovery an open, merit-based competition through Exonic Studio, a no-code tool to combine, prompt and share open-source biological AI models. It repeats the company's claim that Studio beat a state-of-the-art benchmark for liver cancer (HepG2) synthetic enhancer design, validated in its own wet lab, and lists advisors including a former Head of AI at Ginkgo Bioworks.Source
  • 05

    Exonics Therapeutics is a Vertex-owned gene-editing company that delivers its therapy with AAV, the same vector Exonic is building manufacturing programs for. The names are one letter apart, and "exonic" is also an everyday genomics word. A partner who types "Exonic AAV" may land on the wrong company.

    Medium impactLow effort First result in 1-3 months Founder and CEO

    First action

    Search "Exonic AAV" and "Exonic gene therapy" and record what ranks.

    How to measure it

    Branded search share

    Now
    –
    Target
    top 3 results for "Exonic gene therapy" are Exonic's
    By
    90 days

    Steps

    1. 1

      Baseline

      Record results for five branded searches.

      Founder and CEO 1 hour

    2. 2

      Add markup

      Organization schema with legal name and sameAs links.

      Contract web developer 1 hour

    3. 3

      Link profiles

      Site footer links to LinkedIn, X and YC.

      Contract web developer 1 hour

    4. 4

      Add the note

      Not-affiliated line on the fact sheet.

      Founder and CEO 15 minutes

    5. 5

      Use the qualifier

      In bios, decks and press mentions.

      Founder and CEO ongoing

    6. 6

      Re-check

      Same searches after 90 days.

      Founder and CEO 90 days

    First result
    1-3 months
    Cost
    $0
    Owner
    Founder and CEO

    Smallest test

    Add the schema and footer links this week.

    Why it works

    Use "Exonic" with a qualifier wherever the name stands alone (for example "Exonic, the AI-designed regulatory DNA company"). Add Organization markup with the legal name, founding date and sameAs links. Make sure the LinkedIn handle (exonicbio) and X handle (exonicai) are linked from the site, and add a line on the fact sheet saying Exonic is not affiliated with Exonics Therapeutics.

    Search engines and AI assistants decide which entity a name refers to from consistent signals. A few signals placed now stop the confusion from building up as both names appear in AAV news.

    Risks and how to handle them

    • Drawing attention to the other company

      Keep the note factual and in the fact sheet only.

    Builds on

    Evidence

    • Name checkExonics Therapeutics, Inc. is a separate Massachusetts gene-editing company, a Vertex subsidiary since 2019, with a CRISPR/Cas9 therapy delivered by AAV for Duchenne muscular dystrophy: the same field, one letter apart.Source
    • Y Combinator profile"Exonic is an AI-native cell and gene therapeutics company." "We program DNA sequences to be context-aware, unlocking new kinds of genetic therapies." Fall 2025 batch, founded 2025, team of 3, San Francisco; links to LinkedIn (exonicbio) and X (exonicai) accounts.Source
    • Directory profilesHealthcare Discovery's profile says nearly all public information about Exonic comes from directory listings and company statements. It found no paper or preprint for the HepG2 result and no NIH or NSF awards; funding appears as $500K (PitchBook, Tracxn, with different close dates) and as $1M elsewhere; some directories name founders that no other source confirms.Source
  • 06

    The most important hire, a Founding Scientist (Synthetic Genomics) who will own the wet lab, is listed only on YC's job board. Exonic's own site has no careers page, so the role is missing from Google's job listings and from the place candidates check first.

    High impactLow effort First result in 2 weeks Founder and CEO

    First action

    Copy the YC role text into a /careers page draft.

    How to measure it

    Qualified applicants

    Now
    –
    Target
    15
    By
    60 days

    Steps

    1. 1

      Draft the page

      Role, programs, lab, pay range, first six months.

      Founder and CEO half a day

    2. 2

      Add markup

      JobPosting schema with salary and location.

      Contract web developer 2 hours

    3. 3

      Publish and link

      Homepage footer, LinkedIn and X.

      Contract web developer 1 hour

    4. 4

      Seed it

      Share with advisors' labs and synthetic biology groups.

      Chief Scientific Officer 1 week

    5. 5

      Screen

      Short take-home: design an assay for one enhancer.

      Chief Scientific Officer ongoing

    6. 6

      Review

      Applicants by source after 30 days.

      Founder and CEO 30 days

    First result
    2 weeks
    Cost
    $0
    Owner
    Founder and CEO

    Smallest test

    Publish the page and check Google's job results after a week.

    Why it works

    Add /careers with the full role: the cell-type targeting and AAV manufacturing programs, the Dogpatch and MBC BioLabs setup, the salary and equity ranges already public on YC, and what the first six months look like. Add JobPosting markup so it can appear in Google's job results, and link it from the homepage and LinkedIn.

    Founding scientists are recruited from a small pool. A detailed role on the company's own site, findable in job search, reaches people who don't browse YC's board, and doubles as proof that the lab is real.

    Risks and how to handle them

    • Too many unqualified applicants

      List the hands-on assay skills required.

    Builds on

    Evidence

    • HiringFounding Scientist (Synthetic Genomics), San Francisco (Dogpatch site and MBC BioLabs), $120K–$180K plus 0.50%–2.50% equity, 3+ years. The hire owns the wet lab and reports to the founder: validating AI-designed regulatory DNA in mammalian cells, running cell-based assays for synthetic enhancer and expression systems, and advancing cell-type targeting and AAV (viral vector) manufacturing programs; AAV experience is a major plus. Stated first application: "safer, more controllable, and more affordable gene therapies".Source
    • Your websiteSite scan (November 10, 2026): three sitemap files read but 0 page URLs listed; 0 blog posts; no contact, about, careers or pricing page found; the homepage links to /team, a media page at /media/cre and one science@ email address.Source
  • 07

    Change tracking flagged Google Analytics as removed, yet the homepage still loads seven third-party services, including a 186 KB Tag Manager container and Google ad tags. Exonic may be paying the speed cost of tags it no longer uses, without a clear view of who visits: partners, investors or candidates.

    Medium impactLow effort First result in 1 week Founder and CEO

    First action

    Export the Tag Manager container and list each tag.

    How to measure it

    Tracked outreach visits

    Now
    –
    Target
    measured for every pitch
    By
    30 days

    Steps

    1. 1

      List tags

      Every tag, its purpose and its owner.

      Founder and CEO 1 hour

    2. 2

      Remove unused

      Ads and old analytics not in use.

      Contract web developer 1 hour

    3. 3

      Pick one tool

      Lightweight analytics with three events.

      Contract web developer half a day

    4. 4

      Tag links

      UTM links in deck, emails and posts.

      Founder and CEO 1 hour

    5. 5

      Weekly look

      Ten minutes on Mondays.

      Founder and CEO weekly

    6. 6

      Re-test speed

      PageSpeed after the clean-up.

      Contract web developer 1 hour

    First result
    1 week
    Cost
    $0-20 a month
    Owner
    Founder and CEO

    Smallest test

    Pause the ad tags and compare PageSpeed.

    Why it works

    Open the Tag Manager container, list each tag and who owns it, and remove anything unused. Keep one privacy-friendly analytics tool with three events: fact sheet viewed, careers viewed and partner form sent. Add tracked links to outreach emails and the deck so a visit after a pitch can be seen.

    At this stage the useful signal is whether a target partner opened the science page after a meeting. Fewer tags also help the speed fix in idea 2.

    Risks and how to handle them

    • Removing a tag something depends on

      Pause tags first, delete a week later.

    Evidence

    • Your websiteChange tracking since December 3, 2025: the site title changed from "Exonic – Crowdsourcing Drug Discovery" to "Exonic – AI for adaptive medicine." and Google Analytics was flagged as removed. The domain was registered in May 2025.Source
    • PageSpeedMobile performance 25/100 (desktop 64). In Google's phone lab test the main content (the headline "Imagine if medicine could adapt to disease") appears after 14.4 s, with 27.6 s of blocking time; the homepage downloads 13.8 MB, including 2.7 MB of JavaScript and 5 KB of images. Largest fixes: cache lifetimes (about 11.8 s, 2.6 MB) and unused JavaScript (about 8.7 s, 2.0 MB). Real Chrome visitors (75th percentile) see the main content in 2.3 s, which passes, but responsiveness (INP) is 389 ms, above the 200 ms "good" line; layout shift is 0. Seven third-party services load, including Google Tag Manager (186 KB) and Google ad tags.Source

This quarter 10

The core plays for the next three months.

  • 08

    Exonic's headline proof is a claim, repeated by directories, that its designs beat a state-of-the-art benchmark for liver cancer (HepG2) synthetic enhancer design, validated in its own lab. One directory found no paper or preprint behind it. For a partner's scientist that is the difference between a lead and a footnote.

    High impactMedium effort First result in 2 months Chief Scientific Officer

    First action

    Decide which sequences and methods can be made public without weakening patent filings.

    How to measure it

    Inbound partner inquiries

    Now
    –
    Target
    5
    By
    90 days after posting

    Steps

    1. 1

      IP check

      File any provisional before disclosing sequences.

      Founder and CEO 2 weeks

    2. 2

      Assemble data

      Assay results, replicates and controls.

      Founding Scientist (Synthetic Genomics) 1 week

    3. 3

      Write

      Six-page preprint with figures.

      Chief Scientific Officer 2 weeks

    4. 4

      Advisor review

      Two advisors check claims and stats.

      Chief Scientific Officer 1 week

    5. 5

      Post and publish

      bioRxiv plus a summary page on exonic.ai.

      Chief Scientific Officer 1 day

    6. 6

      Share

      Send to target partners' scientists and post a thread.

      Founder and CEO 1 week

    First result
    2 months
    Cost
    Staff time; patent counsel for a provisional
    Owner
    Chief Scientific Officer

    Smallest test

    Post one figure with methods on the research page.

    Why it works

    Write a short bioRxiv preprint: the design method at the level you are comfortable sharing, the sequences or a representative subset, the assay, controls, replicates, and the comparison against the best known sequences. Release the measurement data and put a summary page on exonic.ai linking to it.

    Gene therapy partners are scientists, and a preprint is the cheapest way to make a result checkable. It also gives journalists, investors and AI assistants a primary source to cite.

    Risks and how to handle them

    • Disclosure harms patentability

      File first, then post.

    • Critics find weaknesses

      State limits clearly; it builds trust.

    Evidence

    • Directory profilesStartupHub describes Exonic as aiming to make drug discovery an open, merit-based competition through Exonic Studio, a no-code tool to combine, prompt and share open-source biological AI models. It repeats the company's claim that Studio beat a state-of-the-art benchmark for liver cancer (HepG2) synthetic enhancer design, validated in its own wet lab, and lists advisors including a former Head of AI at Ginkgo Bioworks.Source
    • Directory profilesHealthcare Discovery's profile says nearly all public information about Exonic comes from directory listings and company statements. It found no paper or preprint for the HepG2 result and no NIH or NSF awards; funding appears as $500K (PitchBook, Tracxn, with different close dates) and as $1M elsewhere; some directories name founders that no other source confirms.Source
  • 09

    The founding scientist role names AAV manufacturing as one of two programs. Asimov already sells AAV Edge for payload design through production, which shows manufacturers pay for genetic parts that raise output. A yield gain shows up in a manufacturer's own run within weeks, while a therapy needs years before it proves anything.

    High impactMedium effort First result in 3 months Founder and CEO

    First action

    Write a one-page pilot offer and list ten vector manufacturing teams to approach.

    How to measure it

    Paid manufacturing pilots

    Now
    –
    Target
    2
    By
    2 quarters

    Steps

    1. 1

      Define scope

      Number of designs, assays, timeline and success measure.

      Chief Scientific Officer 1 week

    2. 2

      Set the price

      Pilot fee plus license option.

      Founder and CEO 2 days

    3. 3

      List targets

      Ten contract manufacturers and in-house vector teams.

      Founder and CEO 2 days

    4. 4

      Warm intros

      Ask advisors and YC network for each.

      Founder and CEO 2 weeks

    5. 5

      Run the first

      Design and test in house.

      Founding Scientist (Synthetic Genomics) 6-8 weeks

    6. 6

      Confirm and publish

      Partner confirms titer; agree a case study.

      Founder and CEO 1 month

    First result
    3 months
    Cost
    Lab consumables; covered by the pilot fee
    Owner
    Founder and CEO

    Smallest test

    Pitch the one-pager to three manufacturers and count replies.

    Why it works

    Package a fixed-scope pilot: the partner names a construct and cell line, Exonic designs a small set of expression or regulatory elements, tests them in its lab, and the partner confirms titer in its own process. Agree a fee for the pilot and an option to license the winners. Approach contract manufacturers and in-house vector teams first.

    It produces revenue and a named reference much faster than therapy programs, and the result is a number the partner measures themselves.

    Risks and how to handle them

    • Lab capacity before the hire

      Take one pilot at a time until the founding scientist starts.

    • Partner keeps the IP

      Agree ownership and license terms in the pilot contract.

    Builds on

    Evidence

    • HiringFounding Scientist (Synthetic Genomics), San Francisco (Dogpatch site and MBC BioLabs), $120K–$180K plus 0.50%–2.50% equity, 3+ years. The hire owns the wet lab and reports to the founder: validating AI-designed regulatory DNA in mammalian cells, running cell-based assays for synthetic enhancer and expression systems, and advancing cell-type targeting and AAV (viral vector) manufacturing programs; AAV experience is a major plus. Stated first application: "safer, more controllable, and more affordable gene therapies".Source
    • Competitor researchRivals' own homepages: Dyno Therapeutics, "AI and biotech pioneers building high-performance genetic technologies" focused on gene delivery, with a partnerships section; Asimov, "Intelligent design of living systems", sells AAV Edge for "end-to-end payload design and gene therapy production", with tissue-specific promoters in its parts library and both platform-transfer and done-for-you models; Profluent, "Grounded in nature, authored by AI", promotes OpenCRISPR and partnerships with Eli Lilly and BioMarin.Source
  • 10

    Exonic's stated aim is "safer, more controllable, and more affordable gene therapies" through cell-type targeting. Gene therapy teams that need expression in one cell type, and not its neighbours, have no simple way to buy designed regulatory elements from Exonic today: no offer, no page, no form.

    High impactMedium effort First result in 1 quarter Founder and CEO

    First action

    Write the sprint scope and ask two gene therapy scientists whether they would pay for it.

    How to measure it

    Paid design sprints

    Now
    –
    Target
    2
    By
    2 quarters

    Steps

    1. 1

      Scope

      Inputs, number of designs, assays and timeline.

      Chief Scientific Officer 1 week

    2. 2

      Validate demand

      Five calls with gene therapy researchers.

      Founder and CEO 2 weeks

    3. 3

      Price

      Fixed fee plus license option.

      Founder and CEO 2 days

    4. 4

      Publish the page

      Offer, proof and partner form.

      Contract web developer 2 days

    5. 5

      Outreach

      Twenty targeted emails with the preprint.

      Founder and CEO 1 month

    6. 6

      Deliver and review

      Run, report and ask for a reference.

      Founding Scientist (Synthetic Genomics) 8 weeks

    First result
    1 quarter
    Cost
    Lab consumables; covered by the fee
    Owner
    Founder and CEO

    Smallest test

    Offer the sprint to five researchers by email and count calls booked.

    Why it works

    Publish a design sprint: the partner names the target and off-target cell types, Exonic designs and tests a shortlist of enhancers in relevant cell lines, and delivers ranked sequences with specificity data in a fixed number of weeks for a fixed fee, with a license option. Put it on a page with the HepG2 result as proof.

    A defined deliverable at a known price is easier for a small biotech's head of research to approve than an open-ended partnership.

    Risks and how to handle them

    • Underpricing the lab work

      Price from the real cost of the first sprint plus margin.

    Builds on

    Evidence

    • HiringFounding Scientist (Synthetic Genomics), San Francisco (Dogpatch site and MBC BioLabs), $120K–$180K plus 0.50%–2.50% equity, 3+ years. The hire owns the wet lab and reports to the founder: validating AI-designed regulatory DNA in mammalian cells, running cell-based assays for synthetic enhancer and expression systems, and advancing cell-type targeting and AAV (viral vector) manufacturing programs; AAV experience is a major plus. Stated first application: "safer, more controllable, and more affordable gene therapies".Source
    • Your websiteSite scan (November 10, 2026): three sitemap files read but 0 page URLs listed; 0 blog posts; no contact, about, careers or pricing page found; the homepage links to /team, a media page at /media/cre and one science@ email address.Source
  • 11

    Exonic began as "crowdsourcing drug discovery", with a tournament to beat its HepG2 enhancer results. The site has since dropped that message. But the most useful part of it, an open, independent scoreboard for enhancer design, is something none of the rivals' homepages offer, and it would show Exonic's own designs in context.

    Medium impactMedium effort First result in 2 months Chief Scientific Officer

    First action

    Choose a test set Exonic can release without exposing its training data.

    How to measure it

    Benchmark submissions

    Now
    –
    Target
    15 teams
    By
    6 months

    Steps

    1. 1

      Pick the data

      A releasable held-out set.

      Chief Scientific Officer 2 weeks

    2. 2

      Write scoring

      Open script and rules.

      Founding engineer 1 week

    3. 3

      Build the page

      Leaderboard on exonic.ai, prerendered.

      Contract web developer 1 week

    4. 4

      Launch

      Post with the preprint; email ten labs.

      Founder and CEO 1 week

    5. 5

      Wet-lab round

      Test the top designs quarterly.

      Founding Scientist (Synthetic Genomics) quarterly

    6. 6

      Follow up

      Talk to top teams about hiring or collaboration.

      Founder and CEO ongoing

    First result
    2 months
    Cost
    Staff time plus one assay round per quarter
    Owner
    Chief Scientific Officer

    Smallest test

    Release the test set and scoring script on GitHub and count stars and forks.

    Why it works

    Publish a held-out test set (sequences with measured activity in a few cell types) and a scoring script. Run a leaderboard page where academic groups and companies submit predictions or designs. Exonic tests the top designs in its lab each quarter. Credit the winners and invite them to talk.

    Benchmarks attract the scientists who later become hires, collaborators and partners, and they show Exonic as the reference point in its niche.

    Risks and how to handle them

    • Few submissions

      Seed it with existing open models' scores.

    Builds on

    Evidence

    • Your websiteChange tracking since December 3, 2025: the site title changed from "Exonic – Crowdsourcing Drug Discovery" to "Exonic – AI for adaptive medicine." and Google Analytics was flagged as removed. The domain was registered in May 2025.Source
    • Directory profilesStartupHub describes Exonic as aiming to make drug discovery an open, merit-based competition through Exonic Studio, a no-code tool to combine, prompt and share open-source biological AI models. It repeats the company's claim that Studio beat a state-of-the-art benchmark for liver cancer (HepG2) synthetic enhancer design, validated in its own wet lab, and lists advisors including a former Head of AI at Ginkgo Bioworks.Source
    • Competitor researchRivals' own homepages: Dyno Therapeutics, "AI and biotech pioneers building high-performance genetic technologies" focused on gene delivery, with a partnerships section; Asimov, "Intelligent design of living systems", sells AAV Edge for "end-to-end payload design and gene therapy production", with tissue-specific promoters in its parts library and both platform-transfer and done-for-you models; Profluent, "Grounded in nature, authored by AI", promotes OpenCRISPR and partnerships with Eli Lilly and BioMarin.Source
  • 12

    Directories still present Exonic Studio, a no-code tool for running open-source biological AI models, as the product. The YC profile now describes a therapeutics company. Either Studio feeds the new business or it is a distraction that confuses visitors.

    Medium impactLow effort First result in 1 month Founder and CEO

    First action

    Pull Studio usage for the last 90 days.

    How to measure it

    Studio-to-call conversion

    Now
    –
    Target
    5% of active users
    By
    90 days

    Steps

    1. 1

      Check usage

      Active users and institutions in 90 days.

      Founding engineer 1 day

    2. 2

      Decide

      Keep as front door or retire.

      Founder and CEO 1 hour

    3. 3

      Add sign-up

      Name, institution, field.

      Founding engineer 3 days

    4. 4

      Add the invitation

      Sprint offer beside results.

      Founding engineer 1 day

    5. 5

      Monthly email

      New models and results.

      Founder and CEO monthly

    6. 6

      Review

      Conversions after 90 days.

      Founder and CEO 90 days

    First result
    1 month
    Cost
    Hosting plus a few engineering days
    Owner
    Founder and CEO

    Smallest test

    Add a "talk to us about a custom design" link in Studio and count clicks.

    Why it works

    Decide in one meeting. If Studio stays, make it a free tool with a light sign-up (name, institution, field), show each run's result next to an invitation to a design sprint (idea 10), and email users monthly with new results. If it goes, redirect /studio to the research page and remove it from directory descriptions.

    Scientists who already run sequence models are the closest audience for paid design work. A tool that captures who they are turns curiosity into a list of leads.

    Risks and how to handle them

    • Sign-up deters academics

      Ask for institution only.

    Builds on

    Evidence

    • Directory profilesStartupHub describes Exonic as aiming to make drug discovery an open, merit-based competition through Exonic Studio, a no-code tool to combine, prompt and share open-source biological AI models. It repeats the company's claim that Studio beat a state-of-the-art benchmark for liver cancer (HepG2) synthetic enhancer design, validated in its own wet lab, and lists advisors including a former Head of AI at Ginkgo Bioworks.Source
    • Y Combinator profile"Exonic is an AI-native cell and gene therapeutics company." "We program DNA sequences to be context-aware, unlocking new kinds of genetic therapies." Fall 2025 batch, founded 2025, team of 3, San Francisco; links to LinkedIn (exonicbio) and X (exonicai) accounts.Source
  • 13

    The only contact route found on the site is a single science@ email address. There is no contact page, so every partner, investor, candidate and journalist lands in the same inbox with no context.

    Medium impactLow effort First result in 2 weeks Founder and CEO

    First action

    Write the four questions.

    How to measure it

    Qualified inquiries

    Now
    –
    Target
    4 a month
    By
    90 days

    Steps

    1. 1

      Write questions

      Four fields, one optional.

      Founder and CEO 1 hour

    2. 2

      Build the form

      On a prerendered /contact page.

      Contract web developer half a day

    3. 3

      Route

      By inquiry type to email and a shared sheet.

      Contract web developer 2 hours

    4. 4

      Prepare replies

      One-pagers for partners, investors and candidates.

      Founder and CEO 1 day

    5. 5

      Link it

      From every page and the fact sheet.

      Contract web developer 1 hour

    6. 6

      Review

      Inquiries by type monthly.

      Founder and CEO monthly

    First result
    2 weeks
    Cost
    $0
    Owner
    Founder and CEO

    Smallest test

    Add the form to the homepage only.

    Why it works

    Add /contact with a four-question form: who you are (gene therapy developer, manufacturer, investor, researcher, press), your target or cell type, timeline, and a free-text field. Route each type to the right person and reply within one working day with a relevant one-pager.

    Sorting at the door saves founder time and shows a partner the company has a process. It also lets Exonic see which segment is actually reaching out.

    Risks and how to handle them

    • Spam

      Add a simple spam filter.

    Builds on

    Evidence

    • Your websiteSite scan (November 10, 2026): three sitemap files read but 0 page URLs listed; 0 blog posts; no contact, about, careers or pricing page found; the homepage links to /team, a media page at /media/cre and one science@ email address.Source
  • 14

    The site has 0 blog posts or research pages. The work the company describes elsewhere, the HepG2 enhancer result and the cell-type targeting and AAV manufacturing programs in its job post, has no home on exonic.ai.

    Medium impactMedium effort First result in 1 month Chief Scientific Officer

    First action

    Pick the first three results that can be shared.

    How to measure it

    Monthly research notes

    Now
    –
    Target
    6
    By
    6 months

    Steps

    1. 1

      Plan

      Six topics in order.

      Chief Scientific Officer 2 hours

    2. 2

      Template

      Figure, result, meaning, limits.

      Chief Scientific Officer 2 hours

    3. 3

      Build /research

      Prerendered list and note pages.

      Contract web developer 2 days

    4. 4

      Write the first

      The HepG2 summary.

      Chief Scientific Officer 1 day

    5. 5

      Share

      LinkedIn, X and partner emails.

      Founder and CEO monthly

    6. 6

      Keep cadence

      One note a month.

      Chief Scientific Officer monthly

    First result
    1 month
    Cost
    Half a day a month
    Owner
    Chief Scientific Officer

    Smallest test

    Publish one note and send it to ten contacts.

    Why it works

    Add /research with a monthly note: one figure, one result, what it means for gene therapy design, and its limits. Alternate model results and wet-lab results. Each note is prerendered, dated and signed by role, with a link to the partner form.

    Partners judge an early biotech on how fast it learns. A steady record of dated results is cheap proof and gives every outreach email something new to link.

    Risks and how to handle them

    • Disclosing too much

      Patent review before each note.

    Builds on

    Evidence

    • Your websiteSite scan (November 10, 2026): three sitemap files read but 0 page URLs listed; 0 blog posts; no contact, about, careers or pricing page found; the homepage links to /team, a media page at /media/cre and one science@ email address.Source
    • HiringFounding Scientist (Synthetic Genomics), San Francisco (Dogpatch site and MBC BioLabs), $120K–$180K plus 0.50%–2.50% equity, 3+ years. The hire owns the wet lab and reports to the founder: validating AI-designed regulatory DNA in mammalian cells, running cell-based assays for synthetic enhancer and expression systems, and advancing cell-type targeting and AAV (viral vector) manufacturing programs; AAV experience is a major plus. Stated first application: "safer, more controllable, and more affordable gene therapies".Source
  • 15

    Exonic has LinkedIn (exonicbio) and X (exonicai) accounts listed on YC, but the site found no links to them and nothing on the site for a post to point to. The people who matter, gene therapy scientists, vector manufacturing leads and biotech investors, are active on both.

    Medium impactLow effort First result in 1 month Founder and CEO

    First action

    Link both accounts from the site footer.

    How to measure it

    Social-sourced calls

    Now
    –
    Target
    3 a quarter
    By
    2 quarters

    Steps

    1. 1

      Link accounts

      Footer and fact sheet.

      Contract web developer 1 hour

    2. 2

      Template

      Five-post thread format.

      Founder and CEO 1 hour

    3. 3

      Post

      One thread per research note.

      Founder and CEO monthly

    4. 4

      Tag

      Advisors and collaborators with consent.

      Founder and CEO monthly

    5. 5

      Follow up

      DM engaged scientists.

      Founder and CEO weekly

    6. 6

      Track

      Tagged links and calls booked.

      Founder and CEO monthly

    First result
    1 month
    Cost
    $0
    Owner
    Founder and CEO

    Smallest test

    Post one thread on the HepG2 result.

    Why it works

    For each research note or preprint, post a short thread: the question, one figure, the result, what's next, and a link to the note. Tag collaborators and advisors where they agree. Follow up with people who engage, using the partner form.

    Founder-led science posts are how small biotechs get noticed by the scientists who run partner evaluations, and the link back builds the site's authority.

    Risks and how to handle them

    • Hype backlash

      Show data and limits in every thread.

    Builds on

    Evidence

    • Y Combinator profile"Exonic is an AI-native cell and gene therapeutics company." "We program DNA sequences to be context-aware, unlocking new kinds of genetic therapies." Fall 2025 batch, founded 2025, team of 3, San Francisco; links to LinkedIn (exonicbio) and X (exonicai) accounts.Source
    • Your websiteSite scan (November 10, 2026): three sitemap files read but 0 page URLs listed; 0 blog posts; no contact, about, careers or pricing page found; the homepage links to /team, a media page at /media/cre and one science@ email address.Source
  • 16

    Exonic lists advisors with senior industry backgrounds, including a former Head of AI at Ginkgo Bioworks, and is in the YC network. For a three-person company, warm introductions are the highest-converting route to partners and the founding scientist hire.

    High impactLow effort First result in 2 weeks Founder and CEO

    First action

    Write the forwardable blurb.

    How to measure it

    Advisor introductions

    Now
    –
    Target
    9 a quarter
    By
    next quarter

    Steps

    1. 1

      Write blurb

      Two paragraphs plus the preprint link.

      Founder and CEO 1 hour

    2. 2

      Map networks

      Which advisor knows which targets.

      Founder and CEO half a day

    3. 3

      Ask

      Three named intros per advisor.

      Founder and CEO 1 day

    4. 4

      Use YC

      Same ask in the YC network.

      Founder and CEO 1 day

    5. 5

      Track

      Intros, calls and outcomes.

      Founder and CEO weekly

    6. 6

      Report back

      Quarterly note to advisors.

      Founder and CEO quarterly

    First result
    2 weeks
    Cost
    $0
    Owner
    Founder and CEO

    Smallest test

    Ask one advisor for three intros this week.

    Why it works

    Each quarter, send each advisor a short list of named target organisations and roles (a vector manufacturing lead, a gene therapy research head, a candidate profile) plus a forwardable two-paragraph blurb and the preprint. Track introductions made and outcomes, and report back to the advisor.

    Specific asks get acted on; general "let me know if you know anyone" requests rarely do. Reporting back keeps advisors engaged.

    Risks and how to handle them

    • Asking too often

      Once a quarter, always specific.

    Builds on

    Evidence

    • Directory profilesStartupHub describes Exonic as aiming to make drug discovery an open, merit-based competition through Exonic Studio, a no-code tool to combine, prompt and share open-source biological AI models. It repeats the company's claim that Studio beat a state-of-the-art benchmark for liver cancer (HepG2) synthetic enhancer design, validated in its own wet lab, and lists advisors including a former Head of AI at Ginkgo Bioworks.Source
    • Y Combinator profile"Exonic is an AI-native cell and gene therapeutics company." "We program DNA sequences to be context-aware, unlocking new kinds of genetic therapies." Fall 2025 batch, founded 2025, team of 3, San Francisco; links to LinkedIn (exonicbio) and X (exonicai) accounts.Source
  • 17

    Exonic's buyers, gene therapy and vector manufacturing scientists, gather at a few specialist meetings a year. A three-person company can't sponsor a booth, but a poster with real data plus pre-booked meetings costs little and puts the results in front of the right people.

    Medium impactMedium effort First result in 1-2 quarters Chief Scientific Officer

    First action

    List the next two relevant meetings and their abstract deadlines.

    How to measure it

    Meetings per event

    Now
    –
    Target
    10
    By
    first event

    Steps

    1. 1

      Pick events

      Two meetings with gene therapy and manufacturing tracks.

      Chief Scientific Officer 1 day

    2. 2

      Submit

      Abstract from the preprint.

      Chief Scientific Officer 1 week

    3. 3

      Pre-book

      Email twenty target attendees.

      Founder and CEO 2 weeks

    4. 4

      Prepare

      Poster, one-pager and pilot offer.

      Founding Scientist (Synthetic Genomics) 2 weeks

    5. 5

      Attend

      Meetings at the poster.

      Founder and CEO event

    6. 6

      Follow up

      Within 48 hours with pilot terms.

      Founder and CEO 1 week

    First result
    1-2 quarters
    Cost
    Travel and registration for two
    Owner
    Chief Scientific Officer

    Smallest test

    Pre-book five meetings at the next event you already plan to attend.

    Why it works

    Submit the HepG2 and targeting results as a poster or talk to one major gene and cell therapy meeting. Two weeks before, email twenty target attendees with the preprint and offer a 20-minute slot at the poster. Bring a one-page pilot offer.

    Poster sessions are where partner scientists check data in person, and booked meetings turn a poster into pipeline.

    Risks and how to handle them

    • Abstract rejected

      Attend anyway with pre-booked meetings.

    Builds on

    Evidence

    • HiringFounding Scientist (Synthetic Genomics), San Francisco (Dogpatch site and MBC BioLabs), $120K–$180K plus 0.50%–2.50% equity, 3+ years. The hire owns the wet lab and reports to the founder: validating AI-designed regulatory DNA in mammalian cells, running cell-based assays for synthetic enhancer and expression systems, and advancing cell-type targeting and AAV (viral vector) manufacturing programs; AAV experience is a major plus. Stated first application: "safer, more controllable, and more affordable gene therapies".Source
    • Directory profilesStartupHub describes Exonic as aiming to make drug discovery an open, merit-based competition through Exonic Studio, a no-code tool to combine, prompt and share open-source biological AI models. It repeats the company's claim that Studio beat a state-of-the-art benchmark for liver cancer (HepG2) synthetic enhancer design, validated in its own wet lab, and lists advisors including a former Head of AI at Ginkgo Bioworks.Source

Big bets 3

Larger plays that can change the trajectory.

  • 18

    Profluent shows the end state for AI-designed biology: named partnerships with large pharma (Eli Lilly, BioMarin). Exonic's pilots (ideas 9 and 10) only pay off if the winning sequences convert into a license with milestones on the partner's program.

    High impactHigh effort First result in 2-3 quarters Founder and CEO

    First action

    Ask two advisors which terms they have seen for licensed genetic elements.

    How to measure it

    Signed licenses

    Now
    –
    Target
    1
    By
    12 months

    Steps

    1. 1

      Benchmark terms

      Advisor and counsel input on typical structures.

      Founder and CEO 2 weeks

    2. 2

      Protect the IP

      Provisional filings on lead sequences.

      Founder and CEO 1 month

    3. 3

      Draft term sheet

      Option, upfront, milestones, royalty, field of use.

      Founder and CEO 2 weeks

    4. 4

      Counsel review

      Biotech licensing lawyer.

      Founder and CEO 2 weeks

    5. 5

      Attach to pilots

      Option clause in every pilot contract.

      Founder and CEO ongoing

    6. 6

      Negotiate

      First license from the strongest pilot.

      Founder and CEO 1-2 quarters

    First result
    2-3 quarters
    Cost
    Legal fees for filings and review
    Owner
    Founder and CEO

    Smallest test

    Add an option clause to the first pilot contract.

    Why it works

    Draft a standard term sheet before the first pilot ends: a pilot fee, an option fee, an upfront payment on license, development milestones and a low royalty or per-dose fee, with field-of-use limits so the same element can be licensed into different indications. Get biotech counsel to review it and use it in every pilot.

    Deciding terms early speeds negotiations and stops the first partner from setting a low precedent. Milestones turn a small company's designs into a share of programs it could never fund itself.

    Risks and how to handle them

    • Partners insist on owning designs

      Offer exclusivity by field instead of assignment.

    Builds on

    Evidence

    • Competitor researchRivals' own homepages: Dyno Therapeutics, "AI and biotech pioneers building high-performance genetic technologies" focused on gene delivery, with a partnerships section; Asimov, "Intelligent design of living systems", sells AAV Edge for "end-to-end payload design and gene therapy production", with tissue-specific promoters in its parts library and both platform-transfer and done-for-you models; Profluent, "Grounded in nature, authored by AI", promotes OpenCRISPR and partnerships with Eli Lilly and BioMarin.Source
  • 19

    Exonic calls itself a therapeutics company, not a tools vendor, and its hire is for cell-type targeting work. Platform biotechs usually earn the best partnership terms once they own at least one program with in vivo data. The liver result (HepG2) points to an obvious first tissue.

    High impactHigh effort First result in 6 months Chief Scientific Officer

    First action

    Shortlist three indications where off-target expression is a known problem.

    How to measure it

    Program data package

    Now
    –
    Target
    complete
    By
    18 months

    Steps

    1. 1

      Shortlist indications

      Three where targeting matters most.

      Chief Scientific Officer 1 month

    2. 2

      Choose one

      With advisor input on partnerability.

      Founder and CEO 2 weeks

    3. 3

      Design

      Enhancer candidates for the target cells.

      Chief Scientific Officer 2 months

    4. 4

      Validate in vitro

      Specificity across on- and off-target cells.

      Founding Scientist (Synthetic Genomics) 3 months

    5. 5

      First in vivo

      Contract research organisation study.

      Chief Scientific Officer 6 months

    6. 6

      Package and pitch

      Data room for partners.

      Founder and CEO 2 months

    First result
    6 months for in vitro data
    Cost
    Significant: needs the next raise or a partner
    Owner
    Chief Scientific Officer

    Smallest test

    Run one in vitro specificity panel for the shortlisted indication.

    Why it works

    Choose one indication where cell-type-specific expression clearly improves safety, design the regulatory element in house, and take it through in vitro and a first in vivo study (using a contract research organisation). The aim is a data package to partner or license, not to run trials alone.

    One owned program raises the company's value and bargaining power, and it shows the platform works on a real therapeutic problem.

    Risks and how to handle them

    • Spreads a three-person team too thin

      Start only after the founding scientist is in place and pilots are running.

    Builds on

    Evidence

    • Y Combinator profile"Exonic is an AI-native cell and gene therapeutics company." "We program DNA sequences to be context-aware, unlocking new kinds of genetic therapies." Fall 2025 batch, founded 2025, team of 3, San Francisco; links to LinkedIn (exonicbio) and X (exonicai) accounts.Source
    • HiringFounding Scientist (Synthetic Genomics), San Francisco (Dogpatch site and MBC BioLabs), $120K–$180K plus 0.50%–2.50% equity, 3+ years. The hire owns the wet lab and reports to the founder: validating AI-designed regulatory DNA in mammalian cells, running cell-based assays for synthetic enhancer and expression systems, and advancing cell-type targeting and AAV (viral vector) manufacturing programs; AAV experience is a major plus. Stated first application: "safer, more controllable, and more affordable gene therapies".Source
  • 20

    One directory found no NIH or NSF awards for Exonic, and reported funding is a small seed round. Wet-lab validation of designed regulatory DNA for safer gene therapy is the kind of early translational work government small-business grant programs exist for.

    High impactMedium effort First result in 6-9 months Founder and CEO

    First action

    List open small-business solicitations that match gene therapy safety or biomanufacturing.

    How to measure it

    Applications submitted

    Now
    –
    Target
    2
    By
    2 quarters

    Steps

    1. 1

      Find calls

      Matching solicitations and deadlines.

      Founder and CEO 1 week

    2. 2

      Pick a partner

      Academic collaborator with assays.

      Chief Scientific Officer 2 weeks

    3. 3

      Draft aims

      Three specific aims from current work.

      Chief Scientific Officer 2 weeks

    4. 4

      Write

      Full application with preliminary data.

      Chief Scientific Officer 1 month

    5. 5

      Review

      An advisor who has won grants reads it.

      Founder and CEO 1 week

    6. 6

      Submit and repeat

      Resubmit with reviewer feedback.

      Founder and CEO per cycle

    First result
    6-9 months to a decision
    Cost
    Writing time; optional grant consultant
    Owner
    Founder and CEO

    Smallest test

    Write a one-page specific-aims draft and get advisor feedback.

    Why it works

    Pick one program (cell-type targeting or manufacturing yield), write one small-business research grant application with an academic collaborator, and reuse the preprint and research notes as preliminary data. Grant budgets can cover the assays that pilots and the in-house program need.

    Grants extend runway without dilution, and an award is a third-party check on the science that partners and investors notice.

    Risks and how to handle them

    • Writing time pulls from lab work

      Reuse preprint text and limit to one application per cycle.

    Builds on

    Evidence

    • Directory profilesHealthcare Discovery's profile says nearly all public information about Exonic comes from directory listings and company statements. It found no paper or preprint for the HepG2 result and no NIH or NSF awards; funding appears as $500K (PitchBook, Tracxn, with different close dates) and as $1M elsewhere; some directories name founders that no other source confirms.Source
    • HiringFounding Scientist (Synthetic Genomics), San Francisco (Dogpatch site and MBC BioLabs), $120K–$180K plus 0.50%–2.50% equity, 3+ years. The hire owns the wet lab and reports to the founder: validating AI-designed regulatory DNA in mammalian cells, running cell-based assays for synthetic enhancer and expression systems, and advancing cell-type targeting and AAV (viral vector) manufacturing programs; AAV experience is a major plus. Stated first application: "safer, more controllable, and more affordable gene therapies".Source

Wildcards 2

Unexpected experiments, each with a cheap way to test it.

  • 21

    Exonic's new title is "AI for adaptive medicine" and its headline asks you to "imagine if medicine could adapt to disease". The phrase is still loose: it isn't clearly tied to any one company, and nothing on exonic.ai explains what Exonic means by it.

    Medium impactLow effort First result in 2-3 months Founder and CEO

    First action

    Write a 50-word definition.

    How to measure it

    Definition-page visibility

    Now
    –
    Target
    first page of results for the term
    By
    6 months

    Steps

    1. 1

      Define

      A 50-word definition.

      Founder and CEO 1 hour

    2. 2

      Write the page

      Definition, mechanism, evidence, glossary.

      Chief Scientific Officer 2 days

    3. 3

      Publish

      Prerendered, with article markup.

      Contract web developer half a day

    4. 4

      Link

      From the homepage headline and fact sheet.

      Contract web developer 1 hour

    5. 5

      Use it

      In talks, posts and the deck.

      Founder and CEO ongoing

    6. 6

      Check

      Search and AI answers after three months.

      Founder and CEO 3 months

    First result
    2-3 months
    Cost
    $0
    Owner
    Founder and CEO

    Smallest test

    Publish the definition as a homepage section.

    Why it works

    Write a prerendered page, "What is adaptive medicine?": a plain definition (therapies whose genetic control responds to cell type and state), how context-aware regulatory DNA makes it possible, what is proven and what is not, and a short glossary. Link it from the homepage headline and use the definition in talks and posts.

    The company that defines a new term usually becomes the source search engines and AI assistants quote, and the page explains the vision to investors in one link.

    Risks and how to handle them

    • The term already means something else to clinicians

      Acknowledge other uses and define Exonic's meaning precisely.

    Builds on

    Evidence

    • Your websiteChange tracking since December 3, 2025: the site title changed from "Exonic – Crowdsourcing Drug Discovery" to "Exonic – AI for adaptive medicine." and Google Analytics was flagged as removed. The domain was registered in May 2025.Source
    • PageSpeedMobile performance 25/100 (desktop 64). In Google's phone lab test the main content (the headline "Imagine if medicine could adapt to disease") appears after 14.4 s, with 27.6 s of blocking time; the homepage downloads 13.8 MB, including 2.7 MB of JavaScript and 5 KB of images. Largest fixes: cache lifetimes (about 11.8 s, 2.6 MB) and unused JavaScript (about 8.7 s, 2.0 MB). Real Chrome visitors (75th percentile) see the main content in 2.3 s, which passes, but responsiveness (INP) is 389 ms, above the 200 ms "good" line; layout shift is 0. Seven third-party services load, including Google Tag Manager (186 KB) and Google ad tags.Source
    • Your websiteEvery address fetched on November 10, 2026 (the homepage with and without www, /team, /media/cre, /studio, /sitemap.xml and a made-up path) returned the same thing to a reader that does not run JavaScript: the single line "Exonic – AI for adaptive medicine." robots.txt allows all crawlers.Source
  • 22

    Exonic says its edge is training biological models on heterogeneous, noisy datasets, and it already hosts open models in Studio. Many academic and industry labs hold unpublished reporter-assay and expression data that is too messy to publish, which is exactly the kind of data Exonic's approach is built for.

    High impactMedium effort First result in 1 quarter Chief Scientific Officer

    First action

    Draft a one-page data-sharing offer and agreement outline.

    How to measure it

    Partner datasets

    Now
    –
    Target
    3
    By
    2 quarters

    Steps

    1. 1

      Define the offer

      What labs give and get.

      Chief Scientific Officer 1 week

    2. 2

      Agreement

      Data use and publication terms with counsel.

      Founder and CEO 2 weeks

    3. 3

      Shortlist labs

      Ten via advisors and the benchmark.

      Chief Scientific Officer 1 week

    4. 4

      Sign three

      Pilot data partners.

      Chief Scientific Officer 1 quarter

    5. 5

      Deliver results

      Predictions or designs back to each lab.

      Founding engineer 1 month each

    6. 6

      Publish together

      Joint notes or papers.

      Chief Scientific Officer ongoing

    First result
    1 quarter
    Cost
    Compute and legal review
    Owner
    Chief Scientific Officer

    Smallest test

    Ask one advisor's lab for one dataset.

    Why it works

    Offer labs a simple deal: share a dataset under a data agreement and receive fine-tuned predictions or designs for their own system, plus co-authorship where results are published. Start with three labs in the advisors' networks working on enhancers or vector production.

    Each dataset improves the model, each lab becomes a reference and a source of collaborators, and the cost is compute and goodwill rather than cash.

    Risks and how to handle them

    • Data quality or consent issues

      Accept only cell-line and non-patient data at first.

    Builds on

    Evidence

    • HiringFounding Scientist (Synthetic Genomics), San Francisco (Dogpatch site and MBC BioLabs), $120K–$180K plus 0.50%–2.50% equity, 3+ years. The hire owns the wet lab and reports to the founder: validating AI-designed regulatory DNA in mammalian cells, running cell-based assays for synthetic enhancer and expression systems, and advancing cell-type targeting and AAV (viral vector) manufacturing programs; AAV experience is a major plus. Stated first application: "safer, more controllable, and more affordable gene therapies".Source
    • Directory profilesStartupHub describes Exonic as aiming to make drug discovery an open, merit-based competition through Exonic Studio, a no-code tool to combine, prompt and share open-source biological AI models. It repeats the company's claim that Studio beat a state-of-the-art benchmark for liver cancer (HepG2) synthetic enhancer design, validated in its own wet lab, and lists advisors including a former Head of AI at Ginkgo Bioworks.Source

03

How Programmable can help

Where an idea in this playbook is something Programmable builds or runs, it's listed here with what we'd do. Everything else is yours to run.

ProgrammableDigital

Show it, don't just describe it

These ideas need something to show: a demo, a video, an animation, graphics or a deck. Digital turns screenshots or the site into all of them, in the company's own brand.

Make a demo (opens programmable.digital in a new tab)
More example playbooks and reviews

More growth playbooks

Other companies we have researched, each read from what they are hiring for.

  • Metropolis growth strategyAI and computer vision for physical places: checkout-free drive-in, drive-out parking for Members, operation of parking facilities for…21 growth ideas
  • Lunar Energy growth strategyLunar makes an integrated home battery system (the Lunar System, 15 to 30 kWh, with Lunar AI and the Lunar App) and Gridshare, a software…22 growth ideas
  • Dollar Shave Club growth strategyRazors, shave aids, skin, hair and body care sold by subscription and one-off online, on Amazon and in stores, now with a women's line…22 growth ideas
  • Hanlon Stud Welding growth strategyA family-owned Chicago-area supplier of stud welding studs, accessories, gun parts and welders, with rentals, used equipment and repairs…21 growth ideas
  • D.Luxury growth strategyA Los Angeles growth firm for luxury and premium DTC brands that uses its DIGITALRx customer-profit system to find the customers who drive…21 growth ideas
  • 115 Ventures growth strategyA privately held e-commerce group that builds and runs direct-to-consumer brands: TrySpartan (men's hair growth, beard care, men's health…23 growth ideas
  • Titan growth strategyAn SEC-registered investment adviser for tech professionals: a dedicated wealth advisor plus specialists for investments, equity…21 growth ideas
  • Parker growth strategyAn AI creative strategist for paid social: it researches a brand's reviews, competitors, TikTok, Reddit and ad performance, then answers…21 growth ideas

See every playbook and website review

Independent research. Programmable wrote this playbook from public sources, as they stood on November 10, 2026, and cites them throughout. Exonic did not commission, review or endorse it, and Programmable is not affiliated with Exonic. Company and product names are trademarks of their owners, used only to identify them. The ideas are suggestions and opinion, not professional, legal or financial advice, and not statements about how Exonic runs its business.

Something wrong, or do you represent Exonic? Email [email protected] and we will correct it or take it down.

30/60/90 roadmap

What to focus on in each month, and the ideas that carry it.

  1. Days 1 to 307 ideas

    Make the site readable and fast, pick one message, publish a fact sheet and careers page, separate the name from Exonics Therapeutics and take ownership of measurement.

  2. Days 31 to 6010 ideas

    Publish the HepG2 preprint, open a benchmark, package the manufacturing and targeting pilots, give Studio a job, add a partner form, start research notes, founder posts, advisor intros and a meeting plan.

  3. Days 61 to 905 ideas

    Set licensing terms, choose whether to run an in-house program, apply for non-dilutive funding, and test the two wildcards: owning "adaptive medicine" and data-for-access deals.

The research behind the plan

3 research areas, each summarised in a few lines. Open any of them for the full detail.

Customers

What customers say

Customers value gene expression that switches on only in the target cell type. The most cited problem: expression outside the target tissue, which raises safety risk.

  • Designs that have been tested in cells, not just predicted
  • High cost of gene therapies and AAV production
  • In their words: “synthetic enhancers”

Market

Competitive landscape

4 competitors compared: Dyno Therapeutics, Asimov, Profluent and Exonics Therapeutics (Vertex).

  • Gap to exploit: Fixed-scope, lab-validated regulatory element design for small gene therapy teams
  • Dyno Therapeutics: Focus on delivery rather than regulatory control
  • Asimov: Broad catalogue, less depth in context-aware enhancer design

Hiring signals

Exonic has one open role, and it is the company's turning point: a Founding Scientist (Synthetic Genomics) to own the wet lab, validate AI-designed regulatory DNA in mammalian cells and run the cell-type targeting and…

  • Founding Scientist (Synthetic Genomics): Wet-lab validation for cell-type targeting and AAV manufacturing. Ideas 6, 9, 10, 19.

From the team that wrote this playbook

All products
  • ProgrammableAgencyWorking AI systems in days, not quarters (opens programmable.agency in a new tab)
  • ProgrammableInfoAn agent that finds, researches and asks firstNew accounts get 100,000 free enrichment credits with code BETA100K (opens programmable.info in a new tab)
  • ProgrammableDigitalScreenshots in, an animated product demo out (opens programmable.digital in a new tab)
  • ProgrammableWatchKnow the day a supplier falls out of compliance (opens programmable.watch in a new tab)
  • ProgrammableTalkGet registrants for your events, and know who’s coming (opens programmable.talk in a new tab)
  • ProgrammableMediaAn AI note taker, interpreter and webinar host for your calls (opens programmable.media in a new tab)
  • ProgrammablePageText what you need, your customer gets a page that works (opens programmable.page in a new tab)
  • ProgrammableCommunityForums with labelled AI members, never empty (opens programmable.community in a new tab)
ProgrammableMarketing
ExamplesLeaderboardsProductsTermsPrivacyCookiesDPALegalContact

© 2026 AI-Powered Growth Intelligence